Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 39 Recurrence 6 Neoplasms, Plasma Cell 3 Waldenstrom Macroglobulinemia 2 Neoplasms 1 Lung Neoplasms 1 Leukemia, Plasma Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 36 Bevacizumab 25 Cyclophosphamide 22 Blood Specimen Collection 18 Nivolumab 17 Carboplatin 15 Standard of Care 14 Paclitaxel 14 atezolizumab 13 Gemcitabine 13 Exercise 13 Pemetrexed 11 Fluorouracil 11 Doxorubicin 11 Cisplatin 11 Cetuximab 10 Radiotherapy 9 Oxaliplatin 9 Magnetic Resonance Spectroscopy 9 Leucovorin 9 Docetaxel 9 durvalumab 8 abemaciclib 8 Temozolomide 8 Surveys and Questionnaires 8 Rituximab 8 Prednisone 8 Biopsy 8 130-nm albumin-bound paclitaxel 8 olaparib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × carfilzomib × 90 days × Clear all

NCT04263480 2026-05-12

CZAR-1

University of Ulm

Phase 2 Active not recruiting

Waldenstrom Macroglobulinemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡